RBC Capital Maintains Outperform on Aurinia Pharmaceuticals, Lowers Price Target to $8
Portfolio Pulse from Benzinga Newsdesk
RBC Capital analyst Douglas Miehm has maintained an Outperform rating on Aurinia Pharmaceuticals (NASDAQ:AUPH) but lowered the price target from $13 to $8.
February 16, 2024 | 4:13 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
RBC Capital analyst Douglas Miehm maintains an Outperform rating on Aurinia Pharmaceuticals but lowers the price target from $13 to $8.
While the maintenance of an Outperform rating suggests a positive outlook on the company's fundamentals and potential growth, the reduction in the price target could indicate concerns about near-term challenges or market conditions that might affect the stock's performance. This mixed signal could lead to a neutral short-term impact on the stock price as investors weigh the positive rating against the lowered price target expectations.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100